Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592121 · ClinicalTrials.gov registry record · Early Phase 1
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
A Early Phase 1 study, sponsored by Applied Biology.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT03592121: Completed Early Phase 1 study, sponsored by Applied Biology.
NCT03592121 is a Early Phase 1 study that has completed, run by Applied Biology. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03592121, a Early Phase 1 study, has completed, sponsored by Applied Biology.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
Primary Outcome
Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0 Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax. This is a binary grading system: Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship
Interventions
- DRUG Placebo
- DRUG AB-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2019-10-12 |
| Phase | Early Phase 1 |
What the finished NCT03592121 record still lists
NCT03592121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03592121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03592121 about?
NCT03592121 is a clinical study titled "Study to Investigate the Effect of AB-101 in Breast Cancer Survivors". The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
What is the current status of trial NCT03592121?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2018-07-09. Estimated completion is 2019-10-12.
What interventions are being tested in trial NCT03592121?
The interventions under investigation include: Placebo (DRUG), AB-101 (DRUG).
Who is sponsoring clinical trial NCT03592121?
This trial is sponsored by Applied Biology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03592121's enrollment target sits among peer trials
3 1949th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI